M J Graham

Summary

Affiliation: Isis Pharmaceuticals
Country: USA

Publications

  1. doi request reprint Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
    Mark J Graham
    Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    Circ Res 112:1479-90. 2013
  2. ncbi request reprint Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
    Mark J Graham
    Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    J Lipid Res 48:763-7. 2007
  3. ncbi request reprint Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration
    M J Graham
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, 1896 Rutherford Rd, Carlsbad, CA 92008, USA
    Biochem Pharmacol 62:297-306. 2001
  4. ncbi request reprint In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
    M J Graham
    Isis Pharmaceuticals, Inc, Carlbad Research Center, Carlsbad, California, USA
    J Pharmacol Exp Ther 286:447-58. 1998
  5. ncbi request reprint Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice
    M Butler
    Isis Pharmaceuticals, Carlsbad, California, USA
    J Pharmacol Exp Ther 292:489-96. 2000
  6. ncbi request reprint Metabolism of antisense oligonucleotides in rat liver homogenates
    R M Crooke
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 292:140-9. 2000
  7. ncbi request reprint Antisense properties of 2'-O-dimethylaminooxyethyl (2'-O-DMAOE) oligonucleotides
    T P Prakash
    Isis Pharmaceuticals, 2292 Faraday Ave, Carlsbad, California 92008, USA
    Nucleosides Nucleotides Nucleic Acids 20:829-32. 2001
  8. pmc Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models
    Elizabeth P Newberry
    Department of Medicine, School of Medicine, Washington University, St Louis, MO 63110, USA
    Hepatology 48:1097-105. 2008
  9. pmc Inhibition of ADRP prevents diet-induced insulin resistance
    Gladys M Varela
    Department of Medicine, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, 415 Curie Blvd, 712A Clinical Research Bldg, Philadelphia, PA 19104, USA
    Am J Physiol Gastrointest Liver Physiol 295:G621-8. 2008
  10. doi request reprint Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
    Esther Merki
    University of California San Diego, La Jolla, CA 92093 0682, USA
    Circulation 118:743-53. 2008

Collaborators

Detail Information

Publications21

  1. doi request reprint Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
    Mark J Graham
    Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    Circ Res 112:1479-90. 2013
    ..Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. To date, no selective apoC-III therapeutic agent has been evaluated in the clinic...
  2. ncbi request reprint Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
    Mark J Graham
    Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    J Lipid Res 48:763-7. 2007
    ..Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human...
  3. ncbi request reprint Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration
    M J Graham
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, 1896 Rutherford Rd, Carlsbad, CA 92008, USA
    Biochem Pharmacol 62:297-306. 2001
    ..Based upon these data, it would appear that subcellular oligonucleotide disposition and metabolism among rodent species are more divergent than whole organ pharmacokinetics might predict...
  4. ncbi request reprint In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
    M J Graham
    Isis Pharmaceuticals, Inc, Carlbad Research Center, Carlsbad, California, USA
    J Pharmacol Exp Ther 286:447-58. 1998
    ..Our results suggest that although pharmacokinetic parameters vary as a function of hepatic cell type, significant intracellular delivery can be readily achieved in the liver after systemic administration...
  5. ncbi request reprint Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice
    M Butler
    Isis Pharmaceuticals, Carlsbad, California, USA
    J Pharmacol Exp Ther 292:489-96. 2000
    ....
  6. ncbi request reprint Metabolism of antisense oligonucleotides in rat liver homogenates
    R M Crooke
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 292:140-9. 2000
    ....
  7. ncbi request reprint Antisense properties of 2'-O-dimethylaminooxyethyl (2'-O-DMAOE) oligonucleotides
    T P Prakash
    Isis Pharmaceuticals, 2292 Faraday Ave, Carlsbad, California 92008, USA
    Nucleosides Nucleotides Nucleic Acids 20:829-32. 2001
    ..This modification exhibits very high nuclease resistance and efficacy in various biological (ICAM-1, C-raf and PKC-alpha) targets...
  8. pmc Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models
    Elizabeth P Newberry
    Department of Medicine, School of Medicine, Washington University, St Louis, MO 63110, USA
    Hepatology 48:1097-105. 2008
    ....
  9. pmc Inhibition of ADRP prevents diet-induced insulin resistance
    Gladys M Varela
    Department of Medicine, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, 415 Curie Blvd, 712A Clinical Research Bldg, Philadelphia, PA 19104, USA
    Am J Physiol Gastrointest Liver Physiol 295:G621-8. 2008
    ..These results demonstrate an important role for ADRP in the pathogenesis of diet-induced insulin resistance...
  10. doi request reprint Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
    Esther Merki
    University of California San Diego, La Jolla, CA 92093 0682, USA
    Circulation 118:743-53. 2008
    ..Lipoprotein (a) [Lp(a)] is a genetic cardiovascular risk factor that preferentially binds oxidized phospholipids (OxPL) in plasma. There is a lack of therapeutic agents that reduce plasma Lp(a) levels...
  11. pmc In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C- associated liver disease
    Victoria M Rimkunas
    Department of Physiology, Tufts University School of Medicine, Boston, MA 02111, USA
    Hepatology 47:1504-12. 2008
    ..CONCLUSION: This novel NPC1 antisense mouse model will allow delineation of the mechanism by which NPC1 dysfunction leads to liver cell death...
  12. pmc Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
    J Mark Brown
    Department of Pathology, Biochemistry, and Orthopedic Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 283:10522-34. 2008
    ..Collectively, these studies provide the first insight into the hepatic itinerary of cholesterol when cholesterol esterification is inhibited only in the liver, and provide evidence for a novel non-biliary route of fecal sterol loss...
  13. ncbi request reprint Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide
    Yumi Imai
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19010, USA
    Gastroenterology 132:1947-54. 2007
    ..We postulated that a reduction in ADRP would ameliorate hepatic steatosis and improve insulin action...
  14. ncbi request reprint Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice
    Thomas A Bell
    Department of Pathology, Section on Lipid Sciences, Wake Forest University Health Sciences, Medical Center Blvd, Winston Salem, NC 27157, USA
    Arterioscler Thromb Vasc Biol 26:1814-20. 2006
    ..The purpose of this study was to determine the effects of liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) on the development of hypercholesterolemia and atherosclerosis in mice...
  15. ncbi request reprint Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis
    Yuan Li Zhang
    Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    J Biol Chem 281:37603-15. 2006
    ..The mechanism whereby hepatic Ppargamma2 gene expression is increased and how PPARgamma2 stimulates lipogenesis is under investigation...
  16. ncbi request reprint Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide
    Timothy A Vickers
    Department of Functional Genomics, Isis Pharmaceuticals, 1896 Rutherfored Road, Carlsbad, CA 92008, USA
    J Immunol 176:3652-61. 2006
    ....
  17. ncbi request reprint An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
    Rosanne M Crooke
    Cardiovascular Group, Antisense Drug Discovery, Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    J Lipid Res 46:872-84. 2005
    ....
  18. ncbi request reprint Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis
    Kathleen J Myers
    Antisense Drug Discovery, Isis Pharmaceuticals, 2292 Faraday Ave, Carlsbad, CA 92008, USA
    J Neuroimmunol 160:12-24. 2005
    ..These results demonstrate the potential utility of systemically administered antisense oligonucleotides for the treatment of central nervous system inflammation...
  19. pmc 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo
    Thazha P Prakash
    Isis Pharmaceuticals Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Nucleic Acids Res 32:828-33. 2004
    ..These results demonstrate that 2'-O-DMAOE- modified oligonucleotides are useful for antisense-based therapeutics when either RNase H-dependent or RNase H-independent target reduction mechanisms are employed...
  20. ncbi request reprint A mouse monoclonal antibody specific for mouse apoB48 and apoB100 produced by immunizing "apoB39-only" mice with mouse apoB48
    Anh T Nguyen
    Lipoprotein and Atherosclerosis Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, Canada K1Y 4W7
    Biochim Biophys Acta 1761:182-5. 2006
    ..The antibody will be an important reagent for studying mouse models of atherosclerosis. The study also underscores the utility of genetically modified mice for generating mouse mAbs against mouse proteins...
  21. ncbi request reprint Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    John J P Kastelein
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, PO Box 22700, Room F4 159 2, 1100 DE Amsterdam, The Netherlands
    Circulation 114:1729-35. 2006
    ..In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB...